CDK4 and neoplasm: The inhibition of CDK4/6 could trigger anti-tumor immunity, and a preclinical study showed that combining CDK4/6 inhibitor plus PI3K inhibitor with ICIs in TNBC murine model induced a long-lasting tumor regression [107,108].